SWTX - SpringWorks Therapeutics -- Newly Commercial Stage Fully Valued Biotech Means Steer Clear

2024-04-25 14:19:07 ET

Summary

• SpringWorks Therapeutics has received FDA approval for Nirogacestat, marking its entry into the commercial stage biotech industry.
• The company is now facing the challenge of successfully commercializing its therapy.
• With rapidly growing losses and its hefty market cap SpringWorks Therapeutics is a "Hold".

SpringWorks joined the ranks of commercial stage biotechs with FDA approval of its Nirogacestat (OGSIVEO) in treatment of adult patients with progressing desmoid tumors who require systemic treatment....

For further details see: